Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
Clínica Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19.
Clinical leaders from the University of Kentucky's Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.
Contrary to the warnings issued by health agencies worldwide against cigarette smoking amid the coronavirus disease (COVID-19), a new paper suggests the possibility that nicotine, a component of tobacco, could prevent coronavirus infection.
A new paper published on the preprint server medRxiv in April 2020 shows that the use of the already approved drug ivermectin in clinical trials to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)s not feasible. This contradicts earlier reports of its ability to suppress the virus in vitro.
Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours.
A collaborative study led by Monash University's Biomedicine Discovery Institute in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
Researchers at the LSTM's Centre for Drugs and Diagnostics, and University of Buea, Cameroon have developed new models of the tropical eye worm, Loa loa for the development of new drugs against filariasis.
Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease.
Ivermectin is six times more toxic than Moxidectin for insects in charge of the recycling of organic matter. For the first time ever, there is scientific evidence based on physiological studies and this should be taken into account when using antiparasitic agents for livestock.
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
The Berkeley researchers figured out that they could quickly determine who has the Loa loa worm using a smartphone, customized to work like a microscope. They could then skip the medication for those people and give it to everyone else. Kamgno, who received the latest version of the phones in 2016, dubbed the mobile microscopes "revolutionary."
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
UT Southwestern Medical Center researchers have identified a chemical that suppresses the lethal form of a parasitic infection caused by roundworms that affects up to 100 million people and usually causes only mild symptoms.
River blindness, or onchocerciasis, is a disease caused by a parasitic worm found primarily in Africa. The worm (Onchocerca volvulus) is transmitted to humans as immature larvae through bites of infected black flies.
Osaka Researchers, in partnership with other Japanese and U.S. scientists, report a new gene target, KPNB1, for treatment against epithelial ovarian cancer (EOC).
Malaria affects hundreds of millions of people every year, killing more than half a million. Part of the difficulty of eliminating malaria stems from the fact that a large portion of the at-risk population lives in rural areas where access to doctors can be a challenge.
Research teams from the National Institutes of Health and abroad have identified the first inhibitor of an enzyme long thought to be a potential drug target for fighting disease-causing parasites and bacteria.
The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them.
Scientists have sequenced the genome of the parasitic worm responsible for causing onchocerciasis--an eye and skin infection more commonly known as river blindness.